Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PRKCG | P05129 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | PRKX | P51817 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273302 | 0.91 | CYP3A4 (0.46) | ROCK1GSK3BROCK2CYP3A4CYP2D6 | |
| SCHEMBL3280869 | 0.86 | LMNA (0.43) | ROCK1GSK3BROCK2CYP3A4CYP2D6 | |
| SCHEMBL3279268 | 0.85 | GSK3B (0.45) | ROCK1GSK3BROCK2CYP3A4CYP2D6 | |
| SCHEMBL3153625 | 0.82 | CYP3A4 (0.39) | ROCK1GSK3BROCK2CYP3A4CYP2D6 | |
| SCHEMBL3148947 | 0.81 | PDE2A (0.39) | ROCK1GSK3BROCK2CYP3A4CYP2D6 | |
| SCHEMBL3144849 | 0.81 | ROCK1 (0.42) | ROCK1GSK3BROCK2CYP3A4CYP2D6 | |
| SCHEMBL3273858 | 0.80 | GSK3B (0.45) | ROCK1GSK3BROCK2CYP3A4CYP2D6 | |
| SCHEMBL3273280 | 0.80 | TSHR (0.56) | ROCK1GSK3BROCK2CYP3A4CYP2D6 | |
| SCHEMBL3274514 | 0.79 | PDE2A (0.43) | PDE2AKMT2A | |
| SCHEMBL3277620 | 0.79 | CYP3A4 (0.47) | ROCK1GSK3BROCK2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598175-B2 | Heteroarylamide pyrimidone derivatives | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| EP-2162443-B1 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-31 | — | — | EP | claimed |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | claimed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| US-8598175-B2 | Heteroarylamide pyrimidone derivatives | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| EP-2162443-B1 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
| EP-2162443-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008155666-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | DHFR, DPYD, HPRT1 | ROCK1 2047/4885GSK3B 2501/4885ROCK2 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.